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Most Impactful Presentation at the American Transplant
Congress.
The primary effectiveness endpoint was the incidence
of early allograft dysfunction, and the primary safety endpoint was the number of serious adverse events related to
liver grafts. OCS-preserved livers had lower rates of early
allograft dysfunction compared to organs kept in ischemic
cold storage (17.3% vs. 30.5%). They also observed lower
rates of ischemic biliary complications using the OCS device compared to their ischemic cold storage counterparts
one year after transplant (2.6% vs. 9.9%).
The utility of the OCS Liver system in expanding the
donor pool was also evident as nearly twice as many donations after circulatory death (DCD) livers were able to be
safely transplanted compared to the control group (45.9%
vs. 24.5%).
These results, now accompanied by the FDA approval,
mark a very exciting era in the field of organ transplantation. We may observe increases in transplantation volume, and outcomes, both for patients on the waiting list
and those after having received a transplant. The extended
“shelf life” of the organs and the ability to monitor and
recover even organs that were once considered marginal
or high-risk will be vital to this endeavor.
To date, there are now a total of four ex vivo perfusion systems approved by the FDA: two for lungs [XVIVO
Perfusion System (XPS™) by STEEN Solution™ (Göteborg,
Sweden) and OCS Lung by TransMedics], and for the heart
(TransMedics OCS Heart), and one for liver (TransMedics
OCS Liver) platforms. All of these FDA premarket approvals occurred in the past three years, highlighting the rapid
pace of modern progress.
For many years, the transplant community and society
at large have not been able to rescue all patients seeking
organ transplantation. However, we may, at last, be entering an era where the supply curve may begin to rise to
meet the demand, aided by novel ex vivo organ perfusion
systems, to bring about life-changing opportunities for our
patients.

The Federal Drug Administration grants pre-market
approval to TransMedics Organ Care System Liver, a
platform designed to prolong donor organ viability via
ex vivo perfusion in preparation for transplant
On September 29, 2021, the FDA granted pre-market approval to TransMedics (Andover, MA, USA) OCS Liver system, following the approval of the OCS Heart on September
7 and the OCS Lung in April 2018. The TransMedics OCS
Liver is now the only FDA-approved ex vivo perfusion system to prolong the viability of donor livers.
Organ preservation is a critical process to ensure successful organ transplantation. Poor donor organ viability
can have devastating consequences for recipients. The current standard for transporting donor organs is cold static
storage (around 4°C), which bathes the organ in perfusate
and cools the organ to drive down its metabolic demand
and to preserve tissue viability.
However, this is only a temporary measure because organs eventually incur ischemia-mediated injury over time,
with heart and lungs generally limited to a 4- to 6-h window, liver to 12 h, and kidneys to 24 h. Furthermore, cold
storage transport does not allow for dynamic monitoring
of the organ itself, meaning donor organ performance
cannot be confirmed until after implantation.
Ex vivo perfusion systems are artificial platforms designed to mimic the physiological conditions of the organ
after harvest, thereby limiting ischemic injury and simultaneously providing real-time organ performance during
transport.
The FDA based its decision on the OCS PROTECT trial
(NCT0252287): a multi-center, randomized controlled trial
with 300 liver transplant recipients either randomized to
control ischemic cold storage (n = 147) or OCS (n = 153)
for donor liver preservation. The findings were presented
in June of 2021 at the American Transplant Congress. The
importance of their findings was recognized as they were
awarded the winner of The People's Choice Award for
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